


**AMENDMENTS TO THE CLAIMS**

1. (Original) A compound of Formula IA:



Formula IA

or a pharmaceutically acceptable salt thereof, wherein

A is oxygen, sulfur or NR;

R is C<sub>1</sub>-C<sub>7</sub>alkyl, C<sub>2</sub>-C<sub>7</sub>alkenyl, C<sub>2</sub>-C<sub>7</sub>alkynyl, C<sub>1</sub>-C<sub>6</sub>haloalkyl, (C<sub>3</sub>-C<sub>10</sub>carbocycle)C<sub>1</sub>-C<sub>4</sub>alkyl or (4- to 7-membered heterocycloalkyl)C<sub>1</sub>-C<sub>4</sub>alkyl, each of which is substituted with from 0 to 3 substituents independently chosen from hydroxy, halogen, amino, cyano, oxo, C<sub>1</sub>-C<sub>4</sub>alkyl, C<sub>1</sub>-C<sub>4</sub>alkoxy and C<sub>1</sub>-C<sub>2</sub>alkoxycarbonyl;

x is 0, 1 or 2;

J, K and each occurrence of L are chosen from oxygen, sulfur, NH and CH<sub>2</sub>; such that no more than one of J, K and L is chosen from oxygen, sulfur and NH;

R<sub>1</sub> is chosen from:

- i) hydrogen, hydroxy, halogen, amino, cyano, nitro, -CHO, -CONH<sub>2</sub>, C<sub>1</sub>-C<sub>6</sub>haloalkyl and C<sub>1</sub>-C<sub>6</sub>haloalkoxy;
- ii) C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>2</sub>-C<sub>7</sub>alkenyl, C<sub>2</sub>-C<sub>7</sub>alkynyl, C<sub>2</sub>-C<sub>6</sub>alkanoyl, C<sub>1</sub>-C<sub>6</sub>alkoxy, (C<sub>3</sub>-C<sub>7</sub>cycloalkyl)C<sub>0</sub>-C<sub>4</sub>alkyl, (4- to 10-membered heterocycloalkyl)C<sub>0</sub>-C<sub>4</sub>alkyl, mono- and di-(C<sub>1</sub>-C<sub>6</sub>alkyl)aminoC<sub>0</sub>-C<sub>6</sub>alkyl, mono- and di-(C<sub>1</sub>-C<sub>6</sub>alkyl)carboxamide, C<sub>1</sub>-C<sub>6</sub>alkoxycarbonyl, -SO<sub>n</sub>(C<sub>1</sub>-C<sub>6</sub>alkyl), -NH<sub>2</sub>SO<sub>n</sub>C<sub>1</sub>-C<sub>6</sub>alkyl, -(C<sub>0</sub>-C<sub>6</sub>alkyl)SO<sub>n</sub>(C<sub>1</sub>-C<sub>6</sub>alkyl), -SO<sub>n</sub>N(C<sub>1</sub>-C<sub>6</sub>alkyl)(C<sub>1</sub>-C<sub>6</sub>alkyl), and -SO<sub>n</sub>-phenyl, wherein each n is independently 0, 1 or 2, and each of which is substituted with from 0 to 3 substituents independently chosen from hydroxy, halogen, amino, cyano, oxo, C<sub>1</sub>-C<sub>4</sub>alkyl, C<sub>1</sub>-C<sub>4</sub>alkoxy and C<sub>1</sub>-C<sub>2</sub>alkoxycarbonyl; and
- iii) naphthyl, phenyl and 5- to 10-membered heteroaryl, each of which is substituted with from 0 to 3 substituents independently chosen from R<sub>11</sub>;

R<sub>2</sub> and R<sub>3</sub> are independently hydrogen or C<sub>1</sub>-C<sub>6</sub>alkyl;

R<sub>4</sub> represents 1 substituent chosen from:

- i) C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl, C<sub>2</sub>-C<sub>6</sub>alkynyl, C<sub>1</sub>-C<sub>6</sub>alkoxycarbonyl, (C<sub>3</sub>-C<sub>7</sub>cycloalkyl)C<sub>0</sub>-C<sub>4</sub>alkyl and hexahydro-1,3-benzodioxolyl;
- ii) aryl having 1 ring or 2 fused or pendant rings;
- iii) (4- to 10-membered heterocycloalkyl)C<sub>0</sub>-C<sub>4</sub>alkyl;
- iv) phenyl fused to a 5- to 7-membered saturated or partially unsaturated ring that (a) has 0, 1 or 2 ring atoms independently chosen from N, O and S, with remaining ring atoms being carbon, and (b) is substituted with from 0 to 3 substituents independently chosen from halogen, C<sub>1</sub>-C<sub>8</sub>alkyl, C<sub>1</sub>-C<sub>8</sub>alkoxy, C<sub>1</sub>-C<sub>8</sub>haloalkyl, C<sub>1</sub>-C<sub>8</sub>haloalkoxy;
- v) (5- to 10-membered heteroaryl)C<sub>0</sub>-C<sub>4</sub>alkyl, having 1 ring or 2 fused or pendant rings, from 5 to 7 members in each ring, and in at least one ring from 1 to 3 heteroatoms independently selected from N, O, and S, wherein R<sub>4</sub> is not pyrimidyl; and
- vi) groups that are taken together with an R<sub>5</sub> moiety to form a fused phenyl or pyridyl ring;

wherein each of i), ii), iii), iv), v) and vi) is substituted with from 0 to 3 substituents independently chosen from R<sub>11</sub>;

R<sub>5</sub> represents from 0 to 3 substituents independently chosen from hydroxy, halogen, amino, cyano, nitro, -CHO, -CONH<sub>2</sub>, C<sub>1</sub>-C<sub>2</sub>haloalkyl, C<sub>1</sub>-C<sub>2</sub>haloalkoxy, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>alkoxy, C<sub>3</sub>-C<sub>7</sub>cycloalkylC<sub>0</sub>-C<sub>4</sub>alkyl, mono- and di-(C<sub>1</sub>-C<sub>6</sub>alkyl)aminoC<sub>0</sub>-C<sub>6</sub>alkyl, optionally substituted phenyl, and groups that are taken together with R<sub>4</sub> to form a fused, optionally substituted phenyl or pyridyl ring; and

Ar<sub>1</sub> represents

- i) phenyl or naphthyl, each of which is substituted with from 0 to 3 substituents independently chosen from amino, cyano, C<sub>1</sub>-C<sub>4</sub>alkyl, C<sub>1</sub>-C<sub>4</sub>alkoxy, C<sub>1</sub>-C<sub>2</sub>haloalkyl, C<sub>1</sub>-C<sub>2</sub>haloalkoxy, -COOH, -CONH<sub>2</sub>, mono- and di-(C<sub>1</sub>-C<sub>4</sub>alkyl)amino, C<sub>2</sub>-C<sub>4</sub>alkanoyl, C<sub>1</sub>-C<sub>4</sub>sulfonate, C<sub>1</sub>-C<sub>4</sub>alkylsulfonyl, C<sub>1</sub>-C<sub>4</sub>alkylsulfinyl, C<sub>1</sub>-C<sub>4</sub>alkylthio, C<sub>3</sub>-C<sub>6</sub>alkanone, C<sub>2</sub>-C<sub>4</sub>alkyl ether, C<sub>2</sub>-C<sub>4</sub>alkanoyloxy, C<sub>1</sub>-C<sub>4</sub>alkoxycarbonyl and C<sub>1</sub>-C<sub>6</sub>alkylcarboxamide;
- ii) phenyl fused to a 5- to 7-membered saturated or partially unsaturated ring that (a) has 0, 1 or 2 ring atoms independently chosen from N, O and S, with remaining

ring atoms being carbon, and (b) is substituted with from 0 to 3 substituents independently chosen from halogen, C<sub>1</sub>-C<sub>4</sub>alkyl, C<sub>1</sub>-C<sub>4</sub>alkoxy, C<sub>1</sub>-C<sub>2</sub>haloalkyl and C<sub>1</sub>-C<sub>2</sub>haloalkoxy; or

iii) heteroaryl, having 1 ring or 2 fused or pendant rings, from 5 to 7 members in each ring, and in at least one ring from 1 to 3 heteroatoms independently selected from N, O, and S;

wherein each of ii) and iii) is substituted with from 0 to 3 substituents independently chosen from R<sub>11</sub>; and

R<sub>11</sub> is independently chosen at each occurrence from hydroxy, halogen, amino, cyano, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>alkoxy, C<sub>1</sub>-C<sub>6</sub>haloalkyl, C<sub>1</sub>-C<sub>6</sub>haloalkoxy, -COOH, -CONH<sub>2</sub>, -SO<sub>2</sub>NH<sub>2</sub>, mono- and di-(C<sub>1</sub>-C<sub>6</sub>alkyl)amino, C<sub>2</sub>-C<sub>6</sub>alkanoyl, C<sub>1</sub>-C<sub>6</sub>sulfonate, C<sub>1</sub>-C<sub>6</sub>alkylsulfonyl, C<sub>1</sub>-C<sub>6</sub>alkylsulfinyl, C<sub>1</sub>-C<sub>6</sub>alkylthio, C<sub>3</sub>-C<sub>6</sub>alkanone, C<sub>2</sub>-C<sub>6</sub>alkyl ether, C<sub>2</sub>-C<sub>6</sub>alkanoyloxy, C<sub>1</sub>-C<sub>6</sub>alkoxycarbonyl and C<sub>1</sub>-C<sub>6</sub>alkylcarboxamide.

2. (Original) A compound or salt according to claim 1, wherein:

R is chosen from C<sub>1</sub>-C<sub>7</sub>alkyl, C<sub>2</sub>-C<sub>7</sub>alkenyl, C<sub>2</sub>-C<sub>7</sub>alkynyl, (C<sub>3</sub>-C<sub>7</sub>cycloalkyl)C<sub>1</sub>-C<sub>4</sub>alkyl and (4- to 7-membered heterocycloalkyl)C<sub>1</sub>-C<sub>4</sub>alkyl, each of which is substituted with from 0 to 3 substituents independently chosen from hydroxy, halogen, amino, cyano, oxo, C<sub>1</sub>-C<sub>4</sub>alkyl, C<sub>1</sub>-C<sub>4</sub>alkoxy and C<sub>1</sub>-C<sub>2</sub>alkoxycarbonyl;

R<sub>1</sub> is chosen from:

i) hydrogen, hydroxy, halogen, amino, cyano, nitro, -CHO, -CONH<sub>2</sub>, C<sub>1</sub>-C<sub>6</sub>haloalkyl and C<sub>1</sub>-C<sub>6</sub>haloalkoxy;

ii) C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>alkenyl, C<sub>1</sub>-C<sub>6</sub>alkynyl, C<sub>1</sub>-C<sub>6</sub>alkoxy, (C<sub>3</sub>-C<sub>7</sub>cycloalkyl)C<sub>0</sub>-C<sub>2</sub>alkyl, (4- to 10-membered heterocycloalkyl)C<sub>0</sub>-C<sub>2</sub>alkyl, and mono- and di-(C<sub>1</sub>-C<sub>6</sub>alkyl)carboxamide, each of which is substituted with from 0 to 3 substituents independently chosen from hydroxy, halogen, amino, cyano, oxo, C<sub>1</sub>-C<sub>4</sub>alkyl and C<sub>1</sub>-C<sub>4</sub>alkoxy, and

iii) naphthyl, phenyl, pyridyl, thiazolyl, pyrimidinyl and thienyl, each of which is substituted with from 0 to 3 substituents independently chosen from hydroxy, halogen, amino, cyano, -COOH, -CONH<sub>2</sub>, -SO<sub>2</sub>NH<sub>2</sub>, C<sub>1</sub>-C<sub>6</sub>haloalkyl, C<sub>1</sub>-C<sub>6</sub>haloalkoxy, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>alkoxy, C<sub>2</sub>-C<sub>6</sub>alkanoyl, C<sub>1</sub>-C<sub>6</sub>alkylsulfonyl, C<sub>1</sub>-

C<sub>6</sub>alkylsulfinyl, C<sub>1</sub>-C<sub>6</sub>alkylthio, C<sub>3</sub>-C<sub>6</sub>alkanone, C<sub>2</sub>-C<sub>6</sub>alkylether, C<sub>2</sub>-C<sub>6</sub>alkanoyloxy, C<sub>1</sub>-C<sub>6</sub>alkoxycarbonyl and C<sub>1</sub>-C<sub>6</sub>alkylcarboxamide;

R<sub>4</sub>:

- i) represents C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>2</sub>-C<sub>7</sub>alkenyl, C<sub>2</sub>-C<sub>7</sub>alkynyl, C<sub>1</sub>-C<sub>6</sub>alkoxycarbonyl, (C<sub>3</sub>-C<sub>7</sub>cycloalkyl)C<sub>0</sub>-C<sub>4</sub>alkyl, hexahydro-1,3-benzodioxolyl, phenyl, naphthyl or (4- to 7-membered heterocycloalkyl)C<sub>0</sub>-C<sub>4</sub>alkyl, each of which is substituted with from 0 to 3 substituents independently chosen from hydroxy, halogen, amino, cyano, C<sub>1</sub>-C<sub>4</sub>alkyl, C<sub>1</sub>-C<sub>4</sub>alkoxy, C<sub>1</sub>-C<sub>2</sub>haloalkyl, C<sub>1</sub>-C<sub>2</sub>haloalkoxy, -COOH, -CONH<sub>2</sub>, mono- and di-(C<sub>1</sub>-C<sub>4</sub>alkyl)amino, C<sub>2</sub>-C<sub>4</sub>alkanoyl, C<sub>1</sub>-C<sub>4</sub>sulfonate, C<sub>1</sub>-C<sub>4</sub>alkylsulfonyl, C<sub>1</sub>-C<sub>4</sub>alkylsulfinyl, C<sub>1</sub>-C<sub>4</sub>alkylthio, C<sub>3</sub>-C<sub>6</sub>alkanone, C<sub>2</sub>-C<sub>4</sub>alkyl ether, C<sub>2</sub>-C<sub>4</sub>alkanoyloxy, C<sub>1</sub>-C<sub>4</sub>alkoxycarbonyl, and C<sub>1</sub>-C<sub>6</sub>alkylcarboxamide; or
- ii) is phenyl fused to a 5- to 7-membered saturated or partially unsaturated ring that (a) has 0, 1 or 2 ring atoms independently chosen from N, O and S, with remaining ring atoms being carbon, and (b) is substituted with from 0 to 3 substituents independently chosen from halogen, C<sub>1</sub>-C<sub>4</sub>alkyl, C<sub>1</sub>-C<sub>4</sub>alkoxy, C<sub>1</sub>-C<sub>2</sub>haloalkyl and C<sub>1</sub>-C<sub>2</sub>haloalkoxy; or
- iii) is taken together with an R<sub>5</sub> moiety to form a fused phenyl or pyridyl ring that is substituted with from 0 to 3 substituents independently chosen from hydroxy, halogen, amino, cyano, C<sub>1</sub>-C<sub>4</sub>alkyl, C<sub>1</sub>-C<sub>4</sub>alkoxy, C<sub>1</sub>-C<sub>2</sub>haloalkyl, C<sub>1</sub>-C<sub>2</sub>haloalkoxy, -COOH, -CONH<sub>2</sub>, and mono- and di-(C<sub>1</sub>-C<sub>4</sub>alkyl)amino;

R<sub>5</sub> represents from 0 to 3 substituents independently chosen from hydroxy, halogen, amino, cyano, C<sub>1</sub>-C<sub>4</sub>alkyl, C<sub>1</sub>-C<sub>4</sub>alkoxy, C<sub>1</sub>-C<sub>2</sub>haloalkyl, C<sub>1</sub>-C<sub>2</sub>haloalkoxy, -COOH, -CONH<sub>2</sub>, mono- and di-(C<sub>1</sub>-C<sub>4</sub>alkyl)amino, and groups that are taken together with R<sub>4</sub> to form a fused, optionally substituted phenyl or pyridyl ring; and


Ar<sub>1</sub> represents phenyl, naphthyl, pyridyl, pyrimidinyl, pyridizynyl, pyrazynyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, pyrrolyl, oxazolyl, furanyl, indazolyl or thienyl, each of which is substituted with from 0 to 3 substituents independently chosen from amino, cyano, C<sub>1</sub>-C<sub>4</sub>alkyl, C<sub>1</sub>-C<sub>4</sub>alkoxy, C<sub>1</sub>-C<sub>2</sub>haloalkyl, C<sub>1</sub>-C<sub>2</sub>haloalkoxy, -COOH, -CONH<sub>2</sub>, mono- and di-(C<sub>1</sub>-C<sub>4</sub>alkyl)amino, C<sub>2</sub>-C<sub>4</sub>alkanoyl, C<sub>1</sub>-C<sub>4</sub>sulfonate, C<sub>1</sub>-C<sub>4</sub>alkylsulfonyl, C<sub>1</sub>-C<sub>4</sub>alkylsulfinyl, C<sub>1</sub>-C<sub>4</sub>alkylthio, C<sub>3</sub>-C<sub>6</sub>alkanone, C<sub>2</sub>-C<sub>4</sub>alkyl ether, C<sub>2</sub>-C<sub>4</sub>alkanoyloxy, C<sub>1</sub>-C<sub>4</sub>alkoxycarbonyl and C<sub>1</sub>-C<sub>6</sub>alkylcarboxamide.

3. (Currently Amended) A compound or salt according to claim 1 or claim 2, wherein A is oxygen.

4. (Currently Amended) A compound or salt according to claim 1 or claim 2, wherein A is sulfur.


5. (Currently Amended) A compound or salt according to claim 1 or claim 2, wherein A is NR.

6. (Currently Amended) A compound or salt according to claim 1 or claim 2, wherein the compound satisfies Formula II:




Formula II.

7. (Currently Amended) A compound or salt according to claim 1 or claim 2, wherein the compound satisfies Formula III:




Formula III.

8. (Currently Amended) A compound or salt according to claim 1 or claim 2, wherein the compound satisfies Formula IV:




Formula IV.

9. (Currently Amended) A compound or salt according to claim 1-~~or claim 2~~, wherein the compound satisfies Formula V:




Formula V.

10. (Currently Amended) A compound or salt according to claim 1-~~or claim 2~~, wherein the compound satisfies Formula VI:




Formula VI.

11. (Currently Amended) A compound or salt according to claim 1-~~or claim 2~~, wherein the compound satisfies Formula VII:



Formula VII.

12. (Currently Amended) A compound or salt according to claim 1-~~or claim 2~~, wherein the compound satisfies Formula VIII:



Formula VIII


wherein:

K is CH<sub>2</sub> or NH; and

R<sub>6</sub> represents from 0 to 3 substituents independently chosen from hydroxy, halogen, amino, cyano, C<sub>1</sub>C<sub>4</sub>alkyl, C<sub>1</sub>-C<sub>4</sub>alkoxy, C<sub>1</sub>-C<sub>2</sub>haloalkyl, C<sub>1</sub>-C<sub>2</sub>haloalkoxy, -COOH, -CONH<sub>2</sub> and mono- and di-(C<sub>1</sub>-C<sub>4</sub>alkyl)amino.


13. (Cancelled).

14. (Currently Amended) A compound or salt according to claim 1 or claim 2, wherein the compound satisfies Formula IX:




Formula IX.

15. (Currently Amended) A compound or salt according to claim 1 or claim 2, wherein the compound satisfies Formula X:




Formula X.

16. (Currently Amended) A compound or salt according to claim 1 or claim 2, wherein the compound satisfies Formula XI:



Formula XI.

17. (Currently Amended) A compound or salt according to claim 1, wherein the compound satisfies Formula XII:



Formula XII

wherein  $R_6$  represents from 0 to 3 substituents independently chosen from hydroxy, halogen, amino, cyano,  $C_1$ - $C_4$ alkyl,  $C_1$ - $C_4$ alkoxy,  $C_1$ - $C_2$ haloalkyl,  $C_1$ - $C_2$ haloalkoxy, -COOH, -CONH<sub>2</sub> and mono- and di-( $C_1$ - $C_4$ alkyl)amino.

18. (Currently Amended) A compound or salt according to ~~any one of claims 1 to 17~~claim 1, wherein  $R_2$  and  $R_3$  are both hydrogen.

19. (Currently Amended) A compound or salt according to ~~any one of claims 1 to 18~~claim 1, wherein  $Ar_1$  is phenyl, pyridyl, indazolyl or thienyl, each of which is substituted with 0 to 3 substituents independently chosen from  $C_1$ - $C_4$ alkyl,  $C_1$ - $C_4$ alkoxy,  $C_1$ - $C_2$ haloalkyl,  $C_1$ - $C_2$ haloalkoxy and mono- and di-( $C_1$ - $C_2$ alkyl)amino.

20-22. (Cancelled).

23. (Currently Amended) A compound or salt according to ~~any one of claims 2 through 22~~claim 2, wherein  $R_1$  is:

- i) halogen;
- ii)  $C_1$ - $C_6$ alkyl,  $C_2$ - $C_6$ alkenyl,  $C_1$ - $C_6$ alkoxy, ( $C_3$ - $C_7$ cycloalkyl) $C_0$ - $C_4$ alkyl, pyrrolidinyl $C_0$ - $C_2$ alkyl, morpholinyl $C_0$ - $C_2$ alkyl, piperinyl $C_0$ - $C_2$ alkyl or piperazinyl $C_0$ - $C_2$ alkyl, each of which is substituted with from 0 to 3 substituents independently chosen from hydroxy, halogen, amino, cyano, oxo,  $C_1$ - $C_4$ alkyl and  $C_1$ - $C_4$ alkoxy; or
- iii) phenyl or pyridyl, each of which is substituted with from 0 to 3 substituents independently chosen from hydroxy, halogen, amino, cyano, -COOH, -CONH<sub>2</sub>, -SO<sub>2</sub>NH<sub>2</sub>,  $C_1$ - $C_2$ haloalkyl,  $C_1$ - $C_2$ haloalkoxy,  $C_1$ - $C_6$ alkyl,  $C_1$ - $C_6$ alkoxy, and mono- and di-( $C_1$ - $C_4$ alkyl)amino.

24-25. (Cancelled).

26. (Currently Amended) A compound or salt according to ~~any one of claims 5 through 25~~claim 5, wherein  $R$  is  $C_1$ - $C_7$ alkyl,  $C_2$ - $C_7$ alkenyl, ( $C_3$ - $C_7$ cycloalkyl) $C_1$ -



C<sub>4</sub>alkyl or (1,3-dioxylan-2-yl)C<sub>1</sub>-C<sub>4</sub>alkyl, each of which is substituted with from 0 to 3 substituents independently chosen from hydroxy, halogen, amino, cyano, oxo, C<sub>1</sub>-C<sub>4</sub>alkyl and C<sub>1</sub>-C<sub>4</sub>alkoxy.

27. (Cancelled).

28. (Currently Amended) A compound or salt according to ~~any one of claims 3 to 27~~claim 3, wherein R<sub>4</sub> is C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>alkoxycarbonyl or C<sub>3</sub>-C<sub>7</sub>cycloalkyl, each of which is substituted with from 0 to 3 substituents independently chosen from hydroxy, halogen, amino, cyano, C<sub>1</sub>-C<sub>2</sub>alkyl, C<sub>1</sub>-C<sub>2</sub>alkoxy, C<sub>1</sub>-C<sub>2</sub>haloalkyl, C<sub>1</sub>-C<sub>2</sub>haloalkoxy, -COOH, -CONH<sub>2</sub>, and mono- and di-(C<sub>1</sub>-C<sub>4</sub>alkyl)amino.

29. (Currently Amended) A compound or salt according to ~~any one of claims 3 to 27~~claim 3, wherein R<sub>4</sub> is phenylC<sub>0</sub>-C<sub>1</sub>alkyl, pyridylC<sub>0</sub>-C<sub>1</sub>alkyl, pyrimidylC<sub>0</sub>-C<sub>1</sub>alkyl, thienylC<sub>0</sub>-C<sub>1</sub>alkyl, naphthylC<sub>0</sub>-C<sub>1</sub>alkyl, indolylC<sub>0</sub>-C<sub>1</sub>alkyl, benzoxadiazolylC<sub>0</sub>-C<sub>1</sub>alkyl, benzoxazolylC<sub>0</sub>-C<sub>1</sub>alkyl, quinazolinylC<sub>0</sub>-C<sub>1</sub>alkyl, benzothiazolylC<sub>0</sub>-C<sub>1</sub>alkyl or benzimidazolylC<sub>0</sub>-C<sub>1</sub>alkyl, each of which is substituted with from 0 to 2 substituents independently chosen from hydroxy, halogen, amino, cyano, C<sub>1</sub>-C<sub>2</sub>alkyl, C<sub>1</sub>-C<sub>2</sub>alkoxy, C<sub>1</sub>-C<sub>2</sub>haloalkyl, C<sub>1</sub>-C<sub>2</sub>haloalkoxy and mono- and di-(C<sub>1</sub>-C<sub>2</sub>alkyl)amino.

30-35. (Cancelled) .

36. (Currently Amended) A compound or salt according to ~~any one of claims 3 to 33~~claim 3, wherein R<sub>5</sub> represents from 0 to 3 substituents independently chosen from hydroxy, halogen, C<sub>1</sub>-C<sub>2</sub>alkyl, and C<sub>1</sub>-C<sub>2</sub>alkoxy.

37-39. (Cancelled) .

40. (Currently Amended) A pharmaceutical composition comprising at least one compound or salt according to ~~any one of claims 1-35~~claim 1, in combination with a physiologically acceptable carrier or excipient.

41. (Original) A pharmaceutical composition according claim 40, wherein the pharmaceutical composition is formulated as an injectible fluid, an aerosol, a cream, a gel, a pill, a capsule, a syrup, or a transdermal patch.

42. (Currently Amended) A method for inhibiting signal-transducing activity of a cellular C5a receptor, comprising contacting a cell expressing C5a receptor with at least one compound or salt according to ~~any one of claims 1-35~~claim 1, and thereby reducing signal transduction by the C5a receptor.

43. (Original) A method according to claim 42, wherein the cell is contacted *in vivo* in an animal.

44. (Original) A method according to claim 43, wherein the animal is a human.

45. (Cancelled).

46. (Currently Amended) A method for inhibiting binding of C5a to C5a receptor in a human patient, comprising contacting cells expressing C5a receptor with at least one compound or salt according to ~~any one of claims 1-35~~claim 1, in an amount sufficient to detectably inhibit C5a binding to cells expressing a cloned C5a receptor *in vitro*, and thereby inhibiting binding of C5a to the C5a receptor in the patient.

47. (Currently Amended) A method for treating a patient suffering from rheumatoid arthritis, psoriasis, cardiovascular disease, reperfusion injury, or bronchial asthma comprising administering to the patient a C5a receptor modulatory amount of a compound or salt according to ~~any one of claims 1-35~~claim 1.

48. (Currently Amended) A method for treating a patient suffering from stroke, myocardial infarction, atherosclerosis, ischemic heart disease, or ischemia-reperfusion injury comprising administering to the patient a C5a receptor modulatory amount of a compound or salt according to ~~any one of claims 1-35~~claim 1.

49. (Currently Amended) A method for treating a patient suffering from cystic fibrosis or sepsis, comprising administering to a patient in need of such treatment a C5a receptor modulatory amount of a compound or salt according to ~~any one of claims 1-35~~claim 1.

50. (Currently Amended) A method for inhibiting C5a receptor-mediated cellular chemotaxis, comprising contacting mammalian white blood cells with a C5a receptor modulatory amount of a compound or salt according to ~~any one of claims 1-35~~claim 1.

51-55. (Cancelled).

56. (New) A compound or salt according to claim 4, wherein R<sub>4</sub> is C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>alkoxycarbonyl or C<sub>3</sub>-C<sub>7</sub> cycloalkyl, each of which is substituted with from 0 to 3 substituents independently chosen from hydroxy, halogen, amino, cyano, C<sub>1</sub>-C<sub>2</sub>alkyl, C<sub>1</sub>-C<sub>2</sub>alkoxy, C<sub>1</sub>-C<sub>2</sub>haloalkyl, C<sub>1</sub>-C<sub>2</sub>haloalkoxy, -COOH, -CONH<sub>2</sub>, and mono- and di-(C<sub>1</sub>-C<sub>4</sub>alkyl)amino.

57. (New) A compound or salt according to claim 5, wherein R<sub>4</sub> is C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>alkoxycarbonyl or C<sub>3</sub>-C<sub>7</sub> cycloalkyl, each of which is substituted with from 0 to 3 substituents independently chosen from hydroxy, halogen, amino, cyano, C<sub>1</sub>-C<sub>2</sub>alkyl, C<sub>1</sub>-C<sub>2</sub>alkoxy, C<sub>1</sub>-C<sub>2</sub>haloalkyl, C<sub>1</sub>-C<sub>2</sub>haloalkoxy, -COOH, -CONH<sub>2</sub>, and mono- and di-(C<sub>1</sub>-C<sub>4</sub>alkyl)amino.

58. (New) A compound or salt according to claim 4, wherein R<sub>4</sub> is phenylC<sub>0</sub>-C<sub>1</sub>alkyl, pyridylC<sub>0</sub>-C<sub>1</sub>alkyl, pyrimidylC<sub>0</sub>-C<sub>1</sub>alkyl, thienylC<sub>0</sub>-C<sub>1</sub>alkyl, naphthylC<sub>0</sub>-C<sub>1</sub>alkyl, indolylC<sub>0</sub>-C<sub>1</sub>alkyl, benzoxadiazolylC<sub>0</sub>-C<sub>1</sub>alkyl, benzoxazolylC<sub>0</sub>-C<sub>1</sub>alkyl, quinazolinylC<sub>0</sub>-C<sub>1</sub>alkyl, benzothiazolylC<sub>0</sub>-C<sub>1</sub>alkyl or benzimidazolylC<sub>0</sub>-C<sub>1</sub>alkyl, each of which is substituted with from 0 to 2 substituents independently chosen from hydroxy, halogen, amino, cyano, C<sub>1</sub>-C<sub>2</sub> alkyl, C<sub>1</sub>-C<sub>2</sub>alkoxy, C<sub>1</sub>-C<sub>2</sub>haloalkyl, C<sub>1</sub>-C<sub>2</sub>haloalkoxy and mono- and di-(C<sub>1</sub>-C<sub>2</sub>alkyl)amino.

59. (New) A compound or salt according to claim 5, wherein R<sub>4</sub> is phenylC<sub>0</sub>-C<sub>1</sub>alkyl, pyridylC<sub>0</sub>-C<sub>1</sub>alkyl, pyrimidylC<sub>0</sub>-C<sub>1</sub>alkyl, thienylC<sub>0</sub>-C<sub>1</sub>alkyl, naphthylC<sub>0</sub>-C<sub>1</sub>alkyl, indolylC<sub>0</sub>-C<sub>1</sub>alkyl, benzoxadiazolylC<sub>0</sub>-C<sub>1</sub>alkyl, benzoxazolylC<sub>0</sub>-C<sub>1</sub>alkyl, quinazolinylC<sub>0</sub>-C<sub>1</sub>alkyl, benzothiazolylC<sub>0</sub>-C<sub>1</sub>alkyl or benzimidazolylC<sub>0</sub>-C<sub>1</sub>alkyl, each of which is substituted with from 0 to 2 substituents independently chosen from hydroxy, halogen,

amino, cyano, C<sub>1</sub>-C<sub>2</sub> alkyl, C<sub>1</sub>-C<sub>2</sub>alkoxy, C<sub>1</sub>-C<sub>2</sub>haloalkyl, C<sub>1</sub>-C<sub>2</sub>haloalkoxy and mono- and di-(C<sub>1</sub>-C<sub>2</sub>alkyl)amino.

60. (New) A compound or salt according to claim 4, wherein R<sub>5</sub> represents from 0 to 3 substituents independently chosen from hydroxy, halogen, C<sub>1</sub>-C<sub>2</sub>alkyl, and C<sub>1</sub>-C<sub>2</sub>alkoxy.

61. (New) A compound or salt according to claim 5, wherein R<sub>5</sub> represents from 0 to 3 substituents independently chosen from hydroxy, halogen, C<sub>1</sub>-C<sub>2</sub>alkyl, and C<sub>1</sub>-C<sub>2</sub>alkoxy.